HealthQuill DIOSynVax
UK-based DIOSynVax, a biotechnology company,Ā has developed a single candidate vaccine neutralizing immune responses across the spectrum of very diverse H5 subtypes of influenza viruses.
Drugs Health Medical

UKā€™s DIOSynVax develops single candidate vaccine for bird fluĀ virus

UK-based DIOSynVax, a biotechnology company,Ā has developed a single candidate vaccine neutralizing immune responses across the spectrum of very diverse H5 subtypes of influenza.

Read More
DIOSynVax, a spin-out company of the University of Cambridge, is in its final stage of human trials of an antigen-based vaccine candidate to treat all coronaviruses.
Drugs Health Pharma

DIOSynVax to finish coronavirus vaccine trial in humans by month-end

HQ Team September 29, 2023: DIOSynVax, a spin-out company of the University of Cambridge, is in its final stage of human trials of.

Read More